Cardurion Pharmaceuticals Selected as an Endpoints 11 Most Promising Biotech Company
Burlington, Mass., September 27, 2024 – Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company developing next-generation therapeutics for the treatment of cardiovascular diseases, today announced that it has been named as one of the Endpoints 11 most promising private biotechnology companies of 2024. Cardurion has been chosen by the Endpoints News editorial team because of […]
